Frazier Life Sciences Acquisition Corp. II closes $75M IPO at $10.00; FLSC lists on Nasdaq

Frazier Life Sciences Acquisition Corp. II

IPO of 7,500,000 Class A ordinary shares at $10.00 raised $75,000,000 gross; shares began trading on Nasdaq under "FLSC" Oct 14, 2026 and the offering closed Oct 15.
Sponsor Frazier Life Sciences Holdings II, LLC bought 300,000 private placement shares at $10.00 ($3,000,000); not transferable until 30 days after an initial business combination.
Forward purchase agreement: Frazier Life Sciences Public Fund, L.P. committed to buy at least 2,500,000 Class A shares at $10.00 ($25,000,000), closing with the business combination.
$75,000,000 placed in trust at Continental Stock Transfer & Trust; up to $100,000 of interest may pay liquidation costs; combination deadline is 24 months from IPO close.
Led by CEO Albert Cha, Chairman Ben Palleiko and CBO Kevin Li; intends to target biotechnology; Jefferies was sole book-running manager.

item 1.01 item 3.02 item 5.03 item 8.01 item 9.01

This headline and bullets were generated automatically by deepseek-v4.1-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.